Alphamab climbs most in over 8 weeks on progress of breast cancer treatment
11/06/2026 05:31
BUZZ-Alphamab climbs most in over 8 weeks on progress of breast cancer treatment ** Shares of Alphamab Oncology 9966.HK climb 6.9% to HK$7.1, on track for the biggest one-day pct gain since April 13
** Stock touches the highest point since June 5 in the second rising session
** Co says a phase III clinical study of Anbenitamab met the pre-specified primary endpoint of progression-free survival
** Anbenitamab, which is co-developed with CSPC Pharmaceutical's unit Shanghai JMT-Bio Technology, is the first-line treatment for human epidermal growth factor receptor 2 advanced breast cancer
** Shares of CSPC Pharmaceutical 1093.HK slip 1.5%
** YTD, Alphamab stock down 29.1%, CSPC Pharmaceutical down 15.2%, Hang Seng Biotech Index .HSBIO down 17.1%
(Reporting by Donny Kwok)
Recent news on Alphamab Oncology
See all newsAlphamab climbs most in over 8 weeks on progress of breast cancer treatment
Brief: Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint
Brief: Alphamab Oncology Says CEO Buys 554,000 Shares On June 4
Brief: Alphamab Oncology Says Phase III KN026-004 Study Enrolls 521 Patients And Meets Primary Endpoint
Brief: Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint